DXCM vs PTGX
Dexcom vs Protagonist Therapeutics, Inc. — AI-powered side-by-side comparison
VS
PTGX
Protagonist Therapeutics, Inc.
64
Buy
| Metric | DXCM | PTGX |
|---|
| AI Score |
65
|
64
|
| Price |
$89.16
|
$150.52
|
| P/E Ratio |
35.16×
|
127.02×
|
| ROE |
30.5%
|
-21.2%
|
| Revenue Growth YoY |
—
|
—
|
| Gross Margin |
62.5%
|
99.9%
|
| Debt / Equity |
0.53×
|
0.01×
|
| Dividend Yield |
0.0%
|
0.0%
|
| RSI (14) |
65.4
|
61.5
|
| Beta |
1.41
|
1.794
|
| Expected Upside |
+2.3%
|
—
|
AI Committee View
Current Innellis committee reasoning for DXCM versus PTGX.
DXCM leads by 1 points.
DXCM scores 65/100 (Buy) versus PTGX at 64/100 (Buy).
DXCM Committee View
67% agreement
6 analysts
The primary driver is eps growing 79.4% yoy. The main limiting factor is p/e of 34.5 is moderate-to-rich. The committee is constructive but not yet at full conviction.
Bull Case
- ROE of 36.2% shows genuine earnings power backing the valuation — Value
- EPS growing 79.4% YoY — Growth
- 5 consecutive earnings beats -- consistent execution — Growth
Bear Case
- P/E of 34.5 is moderate-to-rich — Value
- Price-to-book of 9.4x prices in significant intangible value — Value
- Weekly RSI at 75 -- overbought on the larger timeframe too — Technical
PTGX Committee View
83% agreement
6 analysts
The committee is genuinely divided. Growth Analyst sees a compelling case — revenue growing 34.8% yoy -- genuine top-line momentum. Value Analyst remains cautious — p/e of 119.8 is expensive by classic value standards. This disagreement is itself the signal — the setup is not clean in either direction.
Bull Case
- Revenue growing 34.8% YoY -- genuine top-line momentum — Growth
- EPS growing 46.0% YoY — Growth
- Quarter-over-quarter growth rate is ACCELERATING, not just positive — Growth
Bear Case
- P/E of 119.8 is expensive by classic value standards — Value
- Price-to-book of 8.9x prices in significant intangible value — Value
- MACD histogram negative -- bearish momentum — Technical